Oxford Gene Technology (OGT) has unveiled its updated SureSeq™ CLL + CNV V3 Panel, offering cutting-edge solutions for chronic lymphocytic leukemia (CLL) research. This next-generation sequencing (NGS) panel integrates proprietary bait designs to expand gene coverage and improve copy number variation (CNV) detection, enabling more precise variant classification.

This innovation stems from direct collaboration with leading CLL researchers, ensuring the panel addresses key challenges in the field. Enhancements include an expanded list of targeted genes, increased probe density for higher resolution, and the use of internal reference DNA to reduce inter-run variability, leading to more confident CNV calls.

Key Features of the SureSeq™ CLL + CNV V3 Panel:

• Expanded Gene Coverage: Targets additional CLL-associated biomarkers.
• Improved CNV Detection: A 38% increase in CNV identification compared to its predecessor.
• Enhanced Sensitivity: Detects TP53 SNVs with variant allele frequencies as low as 1–5%.
• Streamlined Workflow: Integrates with OGT’s complimentary Interpret software for simplified NGS data analysis.
• Validated Performance: 99% concordance with FISH testing and CNV detection down to 20% tumor content.

This upgraded panel ensures researchers gain deeper insights into CLL progression, offering an optimal tool for disease-associated gene profiling.